CoChat
Sign Up
Cited by 303

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Covalent Linkage of Apolipoprotein E to Albumin Nanoparticles Strongly Enhances Drug Transport into the Brain

Michaelis, K., Hoffmann, M.M., Dreis, S., Herbert, E., Alyautdin, R.N., Michaelis, M., Kreuter, J., Langer, K.·2006·The Journal of Pharmacology and Experimental Therapeutics
DOI 10.1124/jpet.105.097139
Open this paper in CoChat — free account

Abstract

Drug delivery to the brain is becoming more and more important but is severely restricted by the blood-brain barrier. Nanoparticles coated with polysorbates have previously been shown to enable the transport of several drugs across the blood-brain barrier, which under normal circumstances is impermeable to these compounds. Apolipoprotein E was suggested to mediate this drug transport across the blood-brain barrier. In the present study, apolipoprotein E was coupled by chemical methods to nanoparticles made of human serum albumin (HSA-NP). Loperamide, which does not cross the blood-brain barrier but exerts antinociceptive effects after direct injection into the brain, was used as model drug. Apolipoprotein E was chemically bound via linkers to loperamide-loaded HSA-NP. This preparation induced antinociceptive effects in the tail-flick test in ICR mice after i.v. injection. In contrast, nanoparticles linked to apolipoprotein E variants that do not recognize lipoprotein receptors failed to induce these effects. These results indicate that apolipoprotein E attached to the surface of nanoparticles facilitates transport of drugs across the blood-brain barrier, probably after interaction with lipoprotein receptors on the brain capillary endothelial cell membranes.

Overview

Integrity signals

Registry

Crossref · 10.1124/jpet.105.097139

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 37

  1. Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, and Kreuter J (1997) Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res (NY) 14: 325–328. · DOI
  2. Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ, and Kreuter J (1998) Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J Microencapsul 15: 67–74. · DOI
  3. Balthasar S, Michaelis K, Dinauer N, von Briesen H, Kreuter J, and Langer K (2005) Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes. Biomaterials 26: 2723–2732. · DOI
  4. Chen H, Gaul F, Guo D, and Maycock A (2000) Determination of loperamide in rat plasma and bovine serum albumin by LC. J Pharm Biomed Anal 22: 555–561. · DOI
  5. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, and Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science (Wash DC) 261: 921–923. · DOI · Paper page
  6. Croy JE, Brandon T, and Komives EA (2004) Two apolipoprotein E mimetic peptides, ApoE(130–149) and ApoE(141–155)2, bind to LRP1. Biochemistry 43: 7328–7335. · DOI
  7. DeHaven-Hudkins DL, Burgos LC, Cassel JA, Daubert JD, DeHaven RN, Mansson E, Nagasaka H, Yu G, and Yaksh T (1999) Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity. J Pharmacol Exp Ther 289: 494–502. · DOI
  8. Dehouck B, Fenart L, Dehouck MP, Pierce A, Torpier G, and Cecchelli R (1997) A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J Cell Biol 138: 877–889. · DOI · Paper page
  9. De Loof H, Rosseneu M, Brasseur R, and Ruysschaert JM (1986) Use of hydrophobicity profiles to predict receptor binding domains on apolipoprotein E and the low density lipoprotein apolipoprotein B-E receptor. Proc Natl Acad Sci USA 83: 2295–2299. · DOI
  10. Dergunov AD (2004) Apolipoprotein E structure and substrate and receptor-binding activities of triglyceride-rich human plasma lipoproteins in normo- and hypertriglyceridemia. Biochemistry (Mosc) 69: 720–737. · DOI
  11. Dong LM, Parkin S, Trakhanov SD, Rupp B, Simmons T, Arnold KS, Newhouse YM, Innerarity TL, and Weisgraber KH (1996) Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia. Nat Struct Biol 3: 718–722. · DOI
  12. Gelderblom H, Verweij J, Nooter K, and Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37: 1590–1598. · DOI
  13. Geselowitz DA and Neckers LM (1995) Bovine serum albumin is a major oligonucleotide-binding protein found on the surface of cultured cells. Antisense Res Dev 5: 213–217. · DOI
  14. Green NM (1990) Avidin and streptavidin. Methods Enzymol 184: 51–67. · DOI
  15. Hoffmann M, Scharnagl H, Panagiotou E, Banghard W, Wieland H, and Marz W (2001) Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy. J Am Soc Nephrol 12: 524–530. · DOI · Paper page
  16. Isabel G, Wright DM, and Henry JL (1981) Design for an inexpensive unit for measuring tail flick latencies. J Pharmacol Methods 5: 241–247. · DOI
  17. Ji ZS, Fazio S, and Mahley RW (1994) Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J Biol Chem 269: 13421–13428. · DOI · Paper page
  18. Kotchetkov R, Cinatl J, Blaheta R, Vogel JU, Karaskova J, Squire J, Hernaiz Driever P, Klingebiel T, and Cinatl J Jr (2003) Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model. Int J Cancer 104: 36–43. · DOI
  19. Kotchetkov R, Driever PH, Cinatl J, Michaelis M, Karaskova J, Blaheta R, Squire JA, Von Deimling A, Moog J, and Cinatl J Jr (2005) Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. Int J Oncol 27: 1029–1037. · DOI
  20. Kreuter J (2002) Transport of drugs across the blood-brain barrier by nanoparticles. Curr Med Chem Central Nervous Syst Agents 2: 241–249. · DOI
  21. Kreuter J (2004) Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J Nanosci Nanotechnol 4: 484–488. · DOI
  22. Kreuter J, Alyautdin RN, Kharkevich DA, and Ivanov AA (1995) Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res 674: 171–174. · DOI
  23. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, and Alyautdin R (2002) Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target 10: 317–325. · DOI · Paper page
  24. Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, and Schubert D (2003) Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm 257: 169–180. · DOI
  25. Langer K, Coester C, Weber C, von Briesen H, and Kreuter J (2000) Preparation of avidin-labeled protein nanoparticles as carriers for biotinylated peptide nucleic acid. Eur J Pharm Biopharm 49: 303–307. · DOI
  26. Lucarelli M, Borrelli V, Fiori A, Cucina A, Granata F, Potenza RL, Scarpa S, Cavallaro A, and Strom R (2002) The expression of native and oxidized LDL receptors in brain microvessels is specifically enhanced by astrocytes-derived soluble factor(s). FEBS Lett 522: 19–23. · DOI
  27. Meresse S, Delbart C, Fruchart JC, and Cecchelli R (1989) Low-density lipoprotein receptor on endothelium of brain capillaries. J Neurochem 53: 340–345. · DOI · Paper page
  28. Michaelis M, Fichtner I, Behrens D, Haider W, Rothweiler F, Mack A, Cinatl J, Doerr HW, and Cinatl J Jr (2006) Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo. Int J Oncol 28: 439–446. · DOI
  29. Nimpf J and Schneider WJ (2000) From cholesterol transport to signal transduction: low density lipoprotein receptor, very low density lipoprotein receptor and apolipoprotein E receptor-2. Biochim Biophys Acta 1529: 287–298. · DOI
  30. Pitas RE, Boyles JK, Lee SH, Hui D, and Weisgraber KH (1987) Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J Biol Chem 262: 14352–14360. · DOI · Paper page
  31. Ribalta J, Vallve JC, Girona J, and Masana L (2003) Apolipoprotein and apolipoprotein receptor genes, blood lipids and disease. Curr Opin Clin Nutr Metab Care 6: 177–187. · DOI
  32. Schneider WJ, Kovanen PT, Brown MS, Goldstein JL, Utermann G, Weber W, Havel RJ, Kotite L, Kane JP, Innerarity TL, et al. (1981) Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits and cows. J Clin Investig 68: 1075–1085. · DOI · Paper page
  33. Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS, Severin SE, Uhl R, Kock M, Geiger KD, et al. (2004) Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 109: 759–767. · DOI
  34. Vasile E, Simionescu M, and Simionescu N (1983) Visualization of the binding, endocytosis and transcytosis of low-density lipoprotein in the arterial endothelium in situ. J Cell Biol 96: 1677–1689. · DOI · Paper page
  35. Wartlick H, Michaelis K, Balthasar S, Strebhardt K, Kreuter J, and Langer K (2004) Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target 12: 461–471. · DOI
  36. Weber C, Coester C, Kreuter J, and Langer K (2000a) Desolvation process and surface characterisation of protein nanoparticles. Int J Pharm 194: 91–102. · DOI
  37. Weber C, Reiss S, and Langer K (2000b) Preparation of surface modified protein nanoparticles by introduction of sulfhydryl groups. Int J Pharm 211: 67–78. · DOI

Cited by

Sorted by citations

Metadata

Authors
Michaelis, K., Hoffmann, M. M., Dreis, S., Herbert, E., Alyautdin, R. N., Michaelis, M., Kreuter, J., & Langer, K.
Venue
The Journal of Pharmacology and Experimental Therapeutics
Publisher
Elsevier BV
Published
2006-06
Volume
317
Issue
3
Pages
1246-1253
ISSN
0022-3565
DOI
10.1124/jpet.105.097139
Cited by
303
References
2
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review